论文部分内容阅读
Eculizumab(h5G1·1)是抑制末端补体成分活化的重组人源型单克隆抗体,其能特异性地键合到人末端补体蛋白C5,通过抑制人补体C5向C5a和C5b的裂解以阻断炎症因子C5a的释放及C5b-9的形成。临床前研究表明该抗体对C5有高度亲和力,能阻断C5a和C5b-9的形成,并保护哺乳动物细胞不受C5b-
Eculizumab (h5G1.1) is a recombinant human-derived monoclonal antibody that inhibits the activation of terminal complement components that specifically binds to human end complement protein C5 and blocks inflammation by inhibiting the cleavage of human complement C5 to C5a and C5b Factor C5a release and C5b-9 formation. Preclinical studies have shown that this antibody has a high affinity for C5, blocks the formation of C5a and C5b-9 and protects mammalian cells from C5b-